Investment Rating - The report maintains a "Buy" rating for the company [3][7][13] Core Views - The company is expected to achieve a core profit growth of approximately 15.7% year-on-year in 2024, reaching HKD 12.7 billion [2][7] - The target price has been adjusted down to HKD 23.1, reflecting a potential upside of 25.7% from the current price [2][7][13] - The adjustments in profit forecasts for 2025 and 2026 are due to changes in wind and solar project utilization rates and average electricity prices, with profit estimates reduced by 22% and 21% respectively [2][7] Financial Performance - The company’s revenue for 2024 is projected at HKD 104.1 billion, with a slight decrease in operating profit estimates for 2025 and 2026 [6][15] - The expected net profit for 2024 is HKD 12.7 billion, with a net profit margin of 12.2% [6][15] - The company is projected to maintain a dividend payout ratio of 40%, with dividend yields of 5.3% and 5.9% for 2024 and 2025 respectively [7] Capacity and Sales Forecast - The total installed capacity is expected to increase from 68,507 MW in 2024 to 78,507 MW in 2025, with a significant rise in renewable energy capacity [8] - The total electricity sales volume is projected to grow from 207,638 GWh in 2024 to 223,796 GWh in 2025 [8] Valuation - The valuation of the thermal power segment is based on a 0.7x 2025E P/B ratio, while the renewable energy segment is valued at 8.0x 2025E P/E [9] - The total estimated value of the company is HKD 119.6 billion, translating to a per-share value of HKD 23.10 [9]

Investment Rating - The report maintains an "Outperform" rating for Genscript Biotech [2][4][6] Core Insights - The deconsolidation of Legend Biotech has led to a significant profit improvement for Genscript, with a profit from discontinued operations of approximately $3 billion, compared to a loss of about $518 million in the same period last year [7][17] - The company expects a positive trend for its continuing business segments in 2025, with projected revenues of $938 million, representing a year-on-year growth of 58% [2][8] - The total equity valuation of Genscript is estimated at $6.296 billion, translating to a target price of HK$22.78 per share [6][17] Summary by Segment Life Sciences Segment - Expected revenue for 2025 is $523 million, with a year-on-year growth rate of 15% and an adjusted operating profit of $104 million, also growing by 15% [13][14] - The segment's revenue in 2024 was approximately $454.9 million, up by 10.2% year-on-year, with an adjusted gross profit of about $237.7 million [14][17] Biologics Development Services Segment - Projected Fee-for-Service revenue for 2025 is $113 million, up by 19% year-on-year [14][17] - The segment's revenue in 2024 was about $95 million, down by 13.2% year-on-year, but showed signs of recovery in the second half of 2024 [14][17] Industrial Synthetic Biology Products Segment - Expected revenue for 2025 is $67 million, with a year-on-year growth rate of 25% [15][17] - The segment's revenue in 2024 was approximately $53.7 million, up by 24.6% year-on-year [14][17] Legend Biotech - Following the deconsolidation, the market capitalization of Legend Biotech was approximately $6.8 billion, with Genscript holding a 47.51% stake valued at about $3.231 billion [16][17]

Investment Rating - The investment rating for JD Group is "Buy" with a target price set at HKD 157.2, maintaining the rating for the next six months [5]. Core Views - JD Group's Q4 2024 performance exceeded expectations, with revenue reaching CNY 347 billion, a year-on-year increase of 13.4%. The company also reported a significant increase in net profit, with Non-GAAP net profit rising by 34.5% to CNY 11.3 billion [1][4]. - The report highlights the positive impact of government subsidies and the optimization of product categories, which are expected to drive sustainable growth in market share and order volume [2][4]. - JD Logistics is expanding its international presence and enhancing operational efficiency, with revenue growth of 10.4% in Q4 2024, indicating a strong performance in both domestic and international markets [3][4]. Summary by Sections Financial Performance - In Q4 2024, JD Group achieved total revenue of CNY 347 billion, with product revenue at CNY 281 billion and service revenue at CNY 66 billion, reflecting year-on-year growth of 14.0% and 10.8% respectively [1]. - For the full year 2024, total revenue was CNY 1,158.8 billion, a 6.8% increase, with Non-GAAP net profit reaching CNY 47.8 billion, up 35.8% [1]. Retail Segment - JD Retail's revenue for Q4 2024 was CNY 307.1 billion, a 14.7% increase, with operating profit rising by 44.7% to CNY 10 billion [2]. - The electronics and home appliances category saw a revenue increase of 15.8%, driven by the "trade-in" policy and service upgrades [2]. Logistics Segment - JD Logistics reported Q4 2024 revenue of CNY 52.1 billion, a 10.4% increase, with operating profit growing by 37.1% to CNY 1.8 billion [3]. - The company is expanding its logistics capabilities internationally, with a focus on enhancing service offerings for overseas clients [3]. Shareholder Returns - JD Group has completed a share buyback of approximately 255 million A shares, totaling around USD 3.6 billion, and has initiated a new buyback plan of up to USD 5 billion over the next 36 months [1][4].

Investment Rating - The report assigns a "Buy" rating to the company 361 Degrees (1361.HK) with a target price of HKD 5.63, indicating a potential upside of 22.7% from the current price of HKD 4.59 [3][8]. Core Insights - The company is expected to achieve a revenue growth of 20% and a net profit growth of 19% for 2024, aligning with expectations. The end-of-period inventory increased by 56% to HKD 2.1 billion due to early stocking for the Spring Festival [5][6]. - The company plans to expand its "super premium store" concept to 100 locations by the end of 2025, aiming to create a store model akin to "Uniqlo" in the sports industry [7][8]. - The report anticipates a revenue growth of 10-15% for 2025, with a net profit margin projected between 10-12% [8]. Financial Performance Summary - For 2024, the company reported a revenue of HKD 10.07 billion, a year-on-year increase of 20%, and a net profit of HKD 1.15 billion, up 19% [5][9]. - The gross profit margin improved by 0.4 percentage points to 41.5%, while the net profit margin remained stable at 11.4% [5][9]. - The report forecasts revenues of HKD 11.24 billion, HKD 12.41 billion, and HKD 13.66 billion for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 11.5%, 10.4%, and 10.1% [8][9]. Inventory and Cash Flow Analysis - The company’s inventory turnover days remained stable at 149 days, with a significant increase in inventory due to early stocking [5][9]. - The operating cash flow for 2024 is projected to be HKD 70 million, reflecting the impact of early inventory stocking [5][9].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company has received approval for the first global Trop2 ADC lung cancer indication, which aligns with previous expectations [7] - The expansion of indications is favorable for commercialization in China, with the company expected to participate in the 2025 national medical insurance negotiations [7] - The potential of the product is gradually being realized, with ongoing global phase III studies for additional lung cancer indications [7] - 2025 is projected to be a pivotal year for the company's product commercialization, with several products expected to be approved [7] Financial Summary - Revenue projections for the company are as follows: - 2023A: 1,540.5 million RMB - 2024E: 1,746.8 million RMB (growth rate: 13.4%) - 2025E: 1,836.7 million RMB (growth rate: 5.2%) - 2026E: 2,877.2 million RMB (growth rate: 56.7%) [2] - The net profit attributable to the parent company is projected to be negative, with figures as follows: - 2023A: -574.1 million RMB - 2024E: -350.1 million RMB - 2025E: -434.6 million RMB - 2026E: -286.1 million RMB [2] - Earnings per share (EPS) is expected to improve from -2.53 in 2023A to -1.26 in 2026E [2] - The company anticipates significant revenue from the product Lukanosatuzumab, with projected sales of 47 million RMB in 2024, 960 million RMB in 2025, and 1,886 million RMB in 2026 [9] Key Assumptions - The company is expected to receive collaboration payments from Merck, totaling approximately 1.7 billion RMB from 2024 to 2026 [8] - The approval of Lukanosatuzumab in November 2024 is anticipated to generate substantial revenue in the following years [8]

证券研究报告 | 公司点评 gszqdatemark 2025 03 13 年 月 日 中创新航（03931.HK） 海外业务可期，入通改善流动性 2025 年 2 月 24 日，公司发布盈利预喜。根据公司初步评估，2024 年公 司净利润介于 7.86-8.74 亿元，较 2023 年的 4.37 亿元同比增长 80%- 100%。业绩增长的主要驱动因素包括： Q1 出货规模值得期待，关注海外业务。根据高工锂电，中创新航 2025Q1 动储电池出货量预计达 20GWh，同比增幅近 150%。其中，面向出口车型 的出货量预计占中创新航动力板块整体出货量的 30%以上，这可能得益 于：1）2024 年 7 月阳光电源与沙特 ALGIHAZ 成功签约当时全球最大储 能项目，容量高达 7.8GWh，中创新航为该项目供应高性能电芯；2）2024 年 11 月，阳光电源再获欧洲市场 4.4GWh 储能订单，中创新航再次为阳 光电源储能项目配套高性能电芯；3）公司和多家国际车企就新平台项目 达成合作，并助力多个国内车企实现整车出口。 2025 年 3 月 10 日起，中创新航被正式纳入港股通。3 月 9 日中创新航 在港 ...

Investment Rating - The report maintains a "Buy" rating for the company [5]. Core Insights - The company is leveraging AI technology to create "AI avatars" of top traditional Chinese medicine (TCM) doctors, which is expected to enhance the efficiency and accessibility of TCM services [2][3]. - The integration of AI is anticipated to significantly improve patient experience by providing personalized health management and reducing the workload of doctors [3]. - The company is projected to release several AI avatars of leading experts by July 2025, which could help alleviate the supply bottleneck of quality TCM resources and accelerate revenue growth [2]. Financial Projections - The adjusted net profit forecasts for 2024, 2025, and 2026 are 409 million, 548 million, and 691 million CNY respectively, with corresponding EPS of 1.68, 2.28, and 2.88 CNY [3][4]. - Revenue is expected to grow from 3,042 million CNY in 2024 to 5,006 million CNY in 2026, reflecting a growth rate of 30.95% in 2024 and 27.80% in 2026 [4][9]. - The company is expected to benefit from the aging population and supportive policies in the TCM sector, enhancing its growth potential [3].

2025 年 03 月 13 日 中银航空租赁 (02588) ——滞俄飞机减计影响出清，交付掣肘与降息放缓成关键 变量 上 市 公 司 非银金融 报告原因：有业绩公布需要点评 买入（维持） | 市场数据： | 2025 年 03 月 13 日 | | --- | --- | | 收盘价（港币） | 61.85 | | 恒生中国企业指数 | 8640.61 | | 52 周最高/最低（港币） | 70.25/53.60 | | H 股市值（亿港币） | 429.25 | | 流通 H 股（百万股） | 694.01 | | 汇率（人民币/港币） | 1.0832 | 一年内股价与基准指数对比走势： -3% 17% 37% 57% HSCEI 中银航空租赁 资料来源：Bloomberg 证券分析师 罗钻辉 A0230523090004 luozh@swsresearch.com 研究支持 金黎丹 A0230123060002 jinld@swsresearch.com 联系人 金黎丹 (8621)23297818× jinld@swsresearch.com 事件：3 月 13 日，中银航空租赁披露 2024 ...

Investment Rating - The report maintains a BUY rating for CGN Mining with a target price of HK$2.36, indicating a potential upside of 55.5% from the current price of HK$1.52 [3]. Core Insights - CGN Mining's profit alert indicates a net profit drop of HK$130-180 million year-on-year for 2024, primarily due to a one-off dividend withholding tax and a fair value loss from share swaps related to Paladin Energy. However, excluding these items, the pretax profit from continuing operations is expected to grow by HK$230-280 million year-on-year, translating to a growth rate of 41-50% [1]. - The company is set to release its full-year results on March 20, 2025, and will host an analyst meeting on March 21, 2025 [1][6]. Financial Summary - Revenue is projected to grow from HK$7,363 million in FY23 to HK$10,992 million in FY24, reflecting a year-on-year growth of 49.3% [2]. - Adjusted net profit is expected to decline from HK$497.1 million in FY23 to HK$443.4 million in FY24, a decrease of 10.8% [2]. - The earnings per share (EPS) is forecasted to decrease from 6.54 HK$ cents in FY23 to 5.83 HK$ cents in FY24 [2]. - The price-to-earnings (P/E) ratio is projected to be 26.1x in FY24, decreasing to 17.1x in FY25 [2]. - The return on equity (ROE) is expected to decline from 13.8% in FY23 to 10.8% in FY24, before recovering to 14.6% in FY25 [2]. Share Performance - The market capitalization of CGN Mining is approximately HK$11,553 million, with an average turnover of HK$72.3 million over the past three months [3]. - The stock has experienced a 1-month decline of 2.6% and a 3-month decline of 7.9% [5]. Shareholding Structure - The major shareholder is China General Nuclear Power Corporation, holding 56.9% of the shares, followed by China Chengtong Holding Group with 10.0% [4].

Investment Rating - The investment rating for Alibaba is "Buy" and is maintained [8]. Core Views - The report highlights the company's strong commitment to technology investment and the potential commercialization opportunities arising from the new AI cycle. The integration of intelligent advertising tools is already contributing to the advertising business, and the commercialization process of Taotian is accelerating. The focus on improving the merchant business environment is expected to optimize the Taobao ecosystem [2][5]. Financial Performance - For FY2025 Q3, Alibaba's revenue reached 280.2 billion yuan, a year-on-year increase of 8%. The Non-GAAP net profit attributable to shareholders was 51.3 billion yuan, up 7% year-on-year, while the net profit attributable to shareholders was 48.9 billion yuan, reflecting a significant year-on-year increase of 239% [5]. Business Segments - Taotian Group: The CMR (Customer Management Revenue) grew by 9% year-on-year, driven by the full-quarter impact of basic software service fees and the increased penetration of comprehensive promotion tools. The EBITA for Taotian Group increased by 2% year-on-year, indicating stable profitability during the commercialization acceleration phase [5]. - AIDC: Revenue grew by 32% year-on-year, although EBITA losses expanded to 5 billion yuan, primarily due to investments aimed at user acquisition during overseas shopping festivals [5]. - Cloud Intelligence Group: Revenue increased by 13% year-on-year, with EBITA growing by 33%. The capital expenditure for FY2025 Q1-Q3 saw a significant increase, reflecting a 259% year-on-year growth [5]. Membership Growth - The number of 88VIP members reached 49 million, with a quarter-on-quarter increase of 3 million and a year-on-year increase of 19 million. This growth is attributed to the optimization of the membership benefits system, which is expected to drive new buyers and orders [5]. Future Profit Projections - The report projects the net profit attributable to shareholders for FY2025, FY2026, and FY2027 to be 139.6 billion yuan, 157.6 billion yuan, and 189.3 billion yuan, respectively [5].